A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A

Completed

Conditions studied: Hemophilia A

In brief

To quantify the seroprevalence of antibodies to AAV5, AAV6, and AAV8 and the seroconversion rate over varying follow-up intervals in subjects with hemophilia A

Key facts

Study ID

NCT04560933

Run by

BioMarin Pharmaceutical

People needed

186

Starts

2020-08-25

Expected to finish

2023-10-20

Last updated by the study team

2024-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects diagnosed with Hemophilia A
• Subjects aged 18years or over at time of entry

You may not qualify if…

• Currently participating in an interventional study of any investigational product, device or procedure.
• Subjects who have been previously treated with AAV vector gene therapy

Where it is running

• Covance Inc — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.